Among patients with gout, treatment with at least 300 mg allopurinol daily was associated with a 13% reduced risk for kidney function decline, according to data published in JAMA Internal Medicine.

Among patients with gout, allopurinol use is associated with a lower risk for urolithiasis compared with benzbromarone. Among patients with gout, allopurinol use is associated with a lower risk for ...

The effects of allopurinol treatment on mortality among patients with gout remain uncertain, with a new meta-analysis finding conflicting results. In a systematic review of the literature that ...

Allopurinol didn't provide renal protection, according to the results of two randomized trials. Researchers have long debated whether hyperuricemia causes decline in renal function. In two randomized ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In the first 6 months of allopurinol therapy, gout flare ...

December 16, 2011 — A retrospective analysis of data from 222 hyperuricemic women with gout who had participated in phase 3 comparative trials showed that febuxostat, 80 mg/d, was more effective than ...

Antibiotic Prophylaxis Cuts Recurrent UTI Risk by 50% Benefit of adding the uricosuric drug to a xanthine oxidase inhibitor persists for up to 2 years, extension study shows. Combination therapy with ...

Allopurinol (Alpuric) is prescribed to treat gouty arthritis and prevent specific kidney stones by reducing high uric acid levels in the blood. Allopurinol (Alpuric) is a xanthine oxidase inhibitor, ...

kidney A higher allopurinol dose provided a protective effect against incident renal failure in elderly patients, according to a study published in Annals of the Rheumatic Diseases. A higher ...

) today announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone. This randomized, double-blind, dose-response 250 ...

Indoco Remedies Ltd has informed BSE that the Company has received the approval from United States Food & Drug Administration (USFDA) to manufacture and market Allopurinol 100 mg & 300 mg ...

Chicago, IL - Results of a phase 3, randomized, double-blind study show that febuxostat (TAP Pharmaceutical Products) is more effective in lowering serum uric acid than the current standard of care, ...